Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

Among diabetes drugs, GLP-1 receptor agonists and SGLT2 inhibitors were associated with greater reduction in the risk for Alzheimer’s disease (AD) than DPP-4 inhibitors, new research showed. “GLP-1 ...

The search for effective dementia prevention continues to challenge medical researchers worldwide. Now, a major study published in JAMA Neurology reveals that certain medications used to treat type 2 ...

The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

GLP-1RA drugs may lower risk of deadly subarachnoid haemorrhage strokes in diabetes patients.

NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle ...

A US team has linked metformin use in older women with type 2 diabetes to a 30% lower risk of dying before 90. But does this ...

Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for depression risk between new GLP-1 ...